Non-Small-Cell Lung Cancer – Access & Reimbursement – Detailed, Expanded Analysis (EU)
MARKET OUTLOOK
Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, which results in a significant financial burden on payers. Costs are set to increase following the approval of additional therapies, such as Pfizer’s Vizimpro for first-line EGFR-mutation-positive NSCLC and Astra Zeneca’s Imfinzi for unresectable Stage III NSCLC. Label expansions of existing treatments to earlier settings will also fuel costs, such as Merck & Co.’s Keytruda in first-line metastatic squamous NSCLC and unresectable Stage III NSCLC. As therapies seek to optimize their place in clinical practice, and EU5 markets strive to constrain healthcare expenditures, payers and prescribers must balance tightening budgets and evolving cost-containment policies with clinical need.
QUESTIONS ANSWERED
- What are current prescribing practices for NSCLC in the EU5, and how do prescribing patterns vary by country?
- How do surveyed prescribers and payers across the EU5 embrace newly launched therapies, such as Vizimpro and Alunbrig? How will prescribing patterns change with the launch of novel agents for NSCLC?
- What key market access challenges will manufacturers of novel NSCLC therapies face? What can they do to encourage optimal pricing and reimbursement terms, and to drive uptake?
- How might evolving healthcare reforms and cost-containment strategies affect reimbursement of novel agents, and to what degree will prescribing constraints present a future hurdle for emerging therapies in the EU5?
PRODUCT DESCRIPTION
European Access & Reimbursement provides integrated brand-level and country-specific analysis of primary market research conducted with payers and prescribers to examine reimbursement dynamics and evaluate the impact of payer policy on prescribing behavior.
GEOGRAPHY
France, Germany, Italy, Spain, and United Kingdom
PRIMARY RESEARCH
- Survey of 250 medical oncologists across the top 5 European markets (50 per country)
- Interviews with 10 payers top 5 European markets (2 per country).
KEY DRUGS COVERED
Keytruda, Opdivo, Tecentriq, Imfinzi, Tagrisso, Tafinlar, Mekinist, Vizimpro, Tarceva, Zykadia, Xalkori, Alunbrig, Alecensa, Avastin, Abraxane, Alimta, Giotrif, Cyramza
CONTENT HIGHLIGHTS
- Actionable recommendations to optimize market access
- Market access success and stumbles
- Market access roadblocks
- Pricing and reimbursement dynamics
- Impact of payer policy and coverage on prescribing
- Market access outlook for emerging therapies
Micaela Vidal-Taylor is an Analyst in the Global Market Access team at DRG, with a particular focus on the EU5. In this role, she produces primary and secondary research-based reports and other insights designed for decision markets within the biopharmaceutical industry.
Micaela holds a PhD in Clinical Medicine from Imperial College London, for which she received a full scholarship from the British Heart Foundation. She also holds a masters degree in Biomedical Sciences from Imperial College London in which she achieved a Distinction, and a masters degree in Pharmacology from the University of Oxford.
Priti Girotra, M.Pharm., Ph.D., is an analyst on the Oncology team at DRG, part of Clarivate. She has authored content on multiple indications, including non-small-cell lung cancer, colorectal cancer, gastroesophageal cancer, malignant melanoma, and multiple myeloma. Prior to joining DRG, Dr. Girotra conducted research on formulation optimization of nanoparticles containing triptan derivatives for effective brain targeting and therapeutic management of migraine, under a DST-INSPIRE Fellowship at G.J. University of Science & Technology in Hisar, India.